---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-010044"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:22:25.415856+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq issues delist determination for Avenue Therapeutics; extension to May 20 granted

## Summary
- Nasdaq Staff issued delist determination on March 26, 2024 for failing Bid Price Rule ($1.00 minimum).
- Company did not regain compliance by March 25, 2024 end of 180-day grace period.
- Nasdaq Hearings Panel granted extension through May 20, 2024; delist notice has no immediate effect.
- Company evaluating options to regain compliance but no assurance of success.

## SEC filing metadata
- accession: 0001437749-24-010044
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774924010044/0001437749-24-010044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774924010044/atxi20240326c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-010044
- JSON: https://secwatch.observer/filing/0001437749-24-010044.json
- Plain text: https://secwatch.observer/filing/0001437749-24-010044.txt

## Key facts
- Listing & Compliance Notices
  AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)
  source text: March 26, 2024, the Staff issued a delist determination with respect to the deficiency, as required by the Nasdaq Listing Rules. Notwithstanding, and as previously disclosed, on February 15, 2024, the Company attended a hearing before the Nasdaq Hearings Panel (the “Panel”), at which the Company presented its plan to evidence compliance with both the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “Equity Rule”) as well as the Bid Price Rule (together with the Bid Price Rule, the “Rules”). By decision dated March 11, 2024, the Panel granted the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774924010044/0001437749-24-010044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.